Your browser is no longer supported. Please, upgrade your browser.
Edgewise Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own8.64% Shs Outstand49.22M Perf Week-8.33%
Market Cap1.33B Forward P/E- EPS next Y- Insider Trans87.42% Shs Float- Perf Month-
Income- PEG- EPS next Q- Inst Own63.80% Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range25.09 - 40.49 Perf YTD-9.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.12% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.93% ATR4.75
Employees19 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility8.78% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.15 Prev Close27.91
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume376.64K Price27.08
Recom- SMA20-10.08% SMA50-10.08% SMA200-10.08% Volume55,897 Change-2.97%
Apr-16-21 07:31PM  
Mar-30-21 04:01PM  
Mar-25-21 10:23PM  
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EPossible Member of 10% GroupMar 30Buy16.00625,00010,000,0003,933,137Mar 30 03:42 PM
ROOT JONATHAN DDirectorMar 30Buy16.0015,625250,00015,625Mar 31 07:12 PM
Thompson Peter A.DirectorMar 30Buy16.00359,3755,750,00013,359,456Mar 31 07:11 PM
ORBIMED ADVISORS LLCDirectorMar 30Buy16.00359,3755,750,00013,359,456Mar 31 07:10 PM
Novo Holdings A/S10% OwnerMar 30Buy16.00625,00010,000,0005,587,207Mar 31 04:36 PM